The landscape of heart failure in the United States is shifting, and the changes are more complex than you might think. A recent analysis suggests that the factors driving heart failure (HF) are evolving, with metabolic issues taking center stage. But here's where it gets controversial: this shift could have significant implications for how we treat and prevent this widespread condition.
Over the past 35 years, the prevalence of heart failure has increased in the U.S., according to registry data. However, the study reveals that the underlying risk factors associated with HF have changed. Researchers observed a rise in obesity, diabetes, and chronic kidney disease, while the presence of elevated blood pressure, high cholesterol, and previous heart attacks decreased. Moreover, cardiovascular mortality in the HF population dropped, and self-reported health and physical function improved.
"These changes reflect a complex interplay between medical innovations, better implementation, and improved clinical management of some risk factors, in parallel with increasing prevalence of other risk factors over the past four decades in the United States," explained lead author Dr. Ahmed Sayed.
But here's a key point: While the overall prevalence of HF has increased, when adjusted for age, the prevalence has remained constant. This suggests that the aging population is a major driver of HF prevalence, not necessarily a worsening of the condition among specific age groups.
Analyzing data from the National Health and Nutrition Examination Survey (NHANES), the study included 83,552 participants. Among them, 3,078 reported a history of HF. The crude prevalence of HF rose from 2.1% to 3.0% between 1988 and 2023, a 43% relative increase.
Looking closer at patients with HF, the prevalence of obesity rose dramatically, from 32.5% in 1988 to 60.4% in 2023. Similarly, impaired glucose homeostasis, diabetes, and chronic kidney disease also increased. Conversely, the proportions of HF patients with elevated blood pressure, hypercholesterolemia, and a history of heart attack decreased.
And this is the part most people miss: These changes in risk factors seem to correlate with the increased use of certain medications, such as ACE inhibitors/ARBs, beta-blockers, and statins, while smoking became less common. The risk of cardiovascular mortality dropped over the years in people with and without HF.
Experts also point out limitations, such as the reliance on self-reported data and the absence of complete information on medication and compliance. One expert noted that heart failure today is very different from what it was in the past, with a rise in heart failure with preserved ejection fraction, often driven by comorbidities. Also, the impact of the COVID-19 pandemic on heart failure might not be fully reflected in the findings because the study only goes through 2023.
This brings us to a critical question: What does this mean for the future of research? The findings emphasize the need for trials targeting metabolism-, kidney-, and aging-related factors in HF. Moreover, it's time for more inclusivity in future studies, as many prior HF trials have excluded patients with high BMI and advanced chronic kidney disease. Prevention in heart failure is also a growing area of interest.
What are your thoughts? Do you think the shift towards metabolic drivers of HF is a significant change? Are you surprised by any of the trends highlighted in this study? Share your opinions in the comments below!
